DB-007-5 / Derm-Biome Pharmaceuticals - LARVOL DELTA

Natural product-based compounds demonstrate potent anti-inflammatory and anti-itch effects in a mouse model of atopic dermatitis (SID 2025) - "In a MC903-induced mouse model of AD, DB007-5 demonstrated strong and concentration dependent inhibition of inflammation score (p<0.05 for 0.5%, 0.75% and 1% concentrations). Further, at 0.75%, DB007-5 reduced scratching (itch) score at Day 12 from 7.2+/-2.70 in vehicle treated group to 0.70+/-0.33, p<0.05), while ruxolitinib 1.5% reduced the scratching score to 1.7+/-0.62, p<0.05). In summary, DB007-5 demonstrated strong anti-inflammatory effects as well as potent inhibition of the primary symptom of AD, namely itch. Further studies are underway to evaluate the potential of DB007-5 as a therapy for AD."

Late-breaking abstract • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL4 • IL5

Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug (GlobeNewswire) - "Derm-Biome Pharmaceuticals, Inc...is pleased to announce that its topical drug DB-007-5 was highly effective at treating atopic dermatitis (AD) and is more potent at reducing itch than the current leading AD drug in a well-established preclinical model of human AD....In the study, DB-007-5 (0.75%) significantly reduced AD-associated inflammation and outperformed Opzelura (1.5% ruxolitinib cream by Incyte Corporation, the current leader in topical AD therapy) in reducing itch."

Preclinical • Atopic Dermatitis